Smith \u0026 Nephew (NYSE:SNN) Loses Buy Rating

August 9, 2018 - By Victoria Pittman

Smith & Nephew plc (NYSE:SNN) Logo

Smith \u0026 Nephew (NYSE:SNN) Receives a Downgrade

In a report shared with investors and clients on Wednesday, 8 August, stock analysts at UBS’s equity research division decreased the rating for Smith \u0026 Nephew (NYSE:SNN) shares from the previous Buy to a Neutral.

Smith & Nephew plc (NYSE:SNN) Ratings Coverage

Among 3 analysts covering Smith \u0026 Nephew SNATS (NYSE:SNN), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Smith \u0026 Nephew SNATS had 5 analyst reports since March 26, 2018 according to SRatingsIntel. The stock has “Sell” rating by Deutsche Bank on Thursday, May 3. UBS downgraded the shares of SNN in report on Wednesday, August 8 to “Neutral” rating. The company was maintained on Wednesday, April 4 by Canaccord Genuity.

The stock increased 0.59% or $0.21 during the last trading session, reaching $35.74. About 25,711 shares traded. Smith & Nephew plc (NYSE:SNN) has risen 3.88% since August 9, 2017 and is uptrending. It has underperformed by 8.69% the S&P500.

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company has market cap of $15.81 billion. The firm offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopic enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It has a 20.38 P/E ratio. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery services and products; knee implant products for specialized knee replacement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat.

Another recent and important Smith & Nephew plc (NYSE:SNN) news was published by which published an article titled: “Tracking Ken Fisher’s Fisher Asset Management Portfolio – Q2 2018 Update” on July 18, 2018.

Smith & Nephew plc (NYSE:SNN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.